Drugs / ASP2205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02314793 | Nov 2014 → Oct 2015 | — | Astellas Pharma Europe B.V. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314793 ↗ |
| Modality | Small molecule | — CHEMBL5095211 ↗ |
| Route | Oral | “ASP2205 or matching placebo will be given as a single oral dose under fasted conditions.” NCT02314793 ↗ |